Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 161-169

  Romanowski, Barbara ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bivalent vaccine; Efficacy; Human papillomavirus; Immunogenicity; Long term; Quadrivalent vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ANTIBODY TITER; DRUG EFFICACY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LONG TERM CARE; MATHEMATICAL MODEL; NONHUMAN; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PROTECTION; REVIEW; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL DISEASES;

EID: 79952471906     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.13690     Document Type: Review

References (62)

1. World Health Organization. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professional 2007; Available at: http://www.who.int/reproductivehealth/publications/cancers/RHR-08-14/en/ index.html. Accessed 16 June 2010.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010; Available from: http://globocan.iarc.fr. Accessed 2 August 2010.
3. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364:249-56. (Pubitemid 38942814)
4. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2008, Toronto, Canada, 2008. April 2008, ISSN 0835-2976; Available at: http://www.cancer.ca/canadawide/about%20cancer/ cancer%20statistics/~/media/CCS/Canada%20wide/Files%20List/English%20files%20 heading/pdf%20not%20in%20publications%20section/ Canadian%20Cancer%20Society%20Statistics%20PDF%202008-614137951.ashx. Accessed 15 June 2010.
5. Cancer Research UK. CancerStats Report; Available at: http://info.cancerresearchuk.org/cancerstats/types/cervix/incidence/#inv. Accessed 15 June 2010.
6. Lerman C, Miller SM, Scarborough R, Hanjani P, Nolte S, Smith D. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991; 165:658-62.
7. French DP, Maissi E, Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer 2004; 9:1887-92. (Pubitemid 40065516)
8. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and metaanalysis. Lancet 2006; 367:489-98. (Pubitemid 43208905)
9. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337:1284; DOI: 10.1136/bmj.a1284.
10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9. (Pubitemid 29406813)
11. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27. (Pubitemid 36159887)
12. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine 2008; 26:1-16.
13. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, Fukumoto L. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002; 35:210-24.
14. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen P, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66. (Pubitemid 44863348)
15. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins A, Schiund A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65. (Pubitemid 39488060)
16. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39. (Pubitemid 47607848)
17. Garçon N. Preclinical development of AS04. In: Davies G, Ed. Vaccine adjuvants, Methods in Molecular Biology 626; DOI 10.1007/978-1-60761- 585-9-2, Springer Science + Business Media, LLC 2010.
18. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85.
19. Paavonen J, Naud P, J Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
20. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. HPV Vaccine Adolescent Study Investigators Network. Immunization of adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71. (Pubitemid 46771257)
21. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40.
22. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DE, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
23. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1916-27.
24. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04- adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol Oncol 2008; 110:1-10.
25. Ho GYF, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42. (Pubitemid 35013424)
26. Viscidi RP, Schiffman M, Hildesheim A, Hildesheim A, Herrero R, Castle PE, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18 or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13:324-7. (Pubitemid 38222568)
27. Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005; 14:283-8. (Pubitemid 40165317)
28. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in world. Summary report 2009; Available at www.who.int/hpvcentre. Accessed 16 June 2010.
29. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-7. (Pubitemid 26014152)
30. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
31. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37. (Pubitemid 37045391)
32. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199-202. (Pubitemid 35471246)
33. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19:877-85.
34. Yang R, Murillo FM, Delannoy MJ, Blosser RL, Yutzy WH, 4th, Uematsu S, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005; 174:7912-9. (Pubitemid 40806301)
35. Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006; 17:517-21. (Pubitemid 44285723)
36. Lehtinen M, Idänpään-Heikkilä I, Lunnas T, Palmroth J, Barr E, Cacciatore R, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006; 17:237-46.
37. Cortés B, Schiffman M, Herrero R, Hildesheim A, Jiménez S, Shea K, et al. Establishment and operation of a biorepository for molecular epidemiologic studies in Costa Rica. Cancer Epidemiol Biomarkers Prev 2010; 19:916-22.
38. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71.
39. Pastrana DV, Buck CB, Pang YYS, Thompson CD, Castle PE, FitzGerald PC, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16. (Pubitemid 38406035)
40. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34.
41. Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, et al. Costa Rica Vaccine Trial (CVT) Group. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16.
42. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
43. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19.
44. Einstein MH. On behalf of the HPV-010 Study Group. Immunogenicity comparison of two prophylactic human papillomavirus (HPV) cervical cancer vaccines at month 24. Abstract and poster presented at the European Research Organisation on Genital Infection and Neoplasia, Monte Carlo, Monaco, February 17-20, 2010.
45. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Nice, France, May 4-8, 2010.
46. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, et al. Long-term persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Abstract presented at the Asia Oceania Research Organization on Genital Infections and Neoplasia, New Delhi, India 26-28 March 2010.
47. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Nice, France, May 4-8, 2010.
48. Petaja T. The HPV-012 Study Group. Long-term persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in preteen/adolescent girls and young women. Abstract presented at the European Research Organisation on Genital Infection and Neoplasia, Monte Carlo, Monaco, 17-20 February 2010.
49. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9. (Pubitemid 46843434)
50. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
51. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010; 17:818-27.
52. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612-9.
53. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. End-of-study results of PATRICIA: a phase III efficacy study of HPV-16/18 AS04-adjuvanted vaccine in young women. Abstract presented at the International Papillomavirus Conference, Montreal, Canada, 3-8 July 2010.
54. Naud P. The HPV PATRICIA Study Group. Crossprotective efficacy of the AS04-adjuvanted HPV-16/18 vaccine against oncogenic HPV-31, -33 and -45. Abstract presented at the European Research Organisation on Genital Infection and Neoplasia, Monte Carlo, Monaco, 17-20 February 2010.
55. Romanowski B. On behalf of the PATRICIA Study Group. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results. Abstract presented at the International Papillomavirus Conference, Montreal, Canada, 3-8 July 2010.
56. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24 year population-based study. Gynecol Oncol 2000; 78:97-105. (Pubitemid 30650338)
57. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39.
58. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
59. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936-44.
60. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, et al. Long-term persistence of anti- HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009; 115:1-6.
61. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007; 25:4324-33. (Pubitemid 46635934)
62. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49. (Pubitemid 44080367)